Gleevec regulatory update

The U.K.'s NICE issued final guidance recommending against the use of 600 or 800 mg/day Glivec imatinib from Novartis to treat unresectable and/or metastatic gastrointestinal stromal tumors (GIST) in patients whose disease has progressed after treatment with a 400 mg/day dose. The decision is in line with a final appraisal determination issued in September (see BioCentury, Sept. 20). ...